Can We Afford the Future of Medicine? The Promise and Price of Cell and Gene Therapies

icon mic

September 21, 2026

The promise of cell and gene therapies is big. They have the ability to address the underlying genetic causes of disease, offering new possibilities for people with serious and previously difficult-to-treat conditions. But as cell and gene therapies move beyond just treating rare diseases to also address conditions such as high cholesterol, the market is being shaped by new questions about access and value. The evidence base for existing therapies also continues to evolve, particularly as researchers assess long-term outcomes for treatments that are often approved based on small patient datasets.

Sarah Emond, President and CEO of the Institute for Clinical and Economic Review (ICER), returns to the Business Group on Health podcast to discuss what has changed in the cell and gene therapy market. The conversation explores evolving evidence, how therapies are priced and paid for, provider capacity, regulatory developments, and the long-term durability of treatment outcomes.

As the number of people who become eligible for cell and gene therapies grows, employers face the challenge of connecting employees and their families to potentially life-changing therapies, while also assessing value and managing financial risk.

Tune in for practical insights into new developments, emerging payment options and how stakeholders across the healthcare ecosystem can work together to balance innovation, access and affordability.

SPEAKERS

Sarah Emond | President and CEO, Institute for Clinical and Economic Review (ICER)

Ellen Kelsay | President and CEO, Business Group on Health

Download Transcript 

Duration 33 min

Subscribe To The Podcast

All Podcasts

Showing items 111-120 of 132
May 17, 2021
Your Workforce is Interviewing Your Building
Dr. Allen speaks about how we can design buildings to reduce the risk of disease transmission, as well as promote optimal health,...
Read more
May 03, 2021
Mental Health Check-In: How We’re Doing and Ways...
Dr. Arthur Evans unpacks the findings from the Stress in America 2021: Pandemic Stress One Year On report, as well as discusses...
Read more
Apr 19, 2021
Overcoming FONO - Fear of Normal
Dr. McBride speaks about pandemic anxiety, how we can confront and overcome FONO and why mental health "defines our health and...
Read more
Apr 05, 2021
Artificial Intelligence in Health Care: Its Perils...
Dr. Obermeyer speaks about the hidden signals in health care data, his research revealing racial bias in health care AI and how we...
Read more
Mar 22, 2021
Burnout: Is Your Organization on Fire?
Jennifer Moss speaks about the scale of the burnout crisis, why it's an organizational problem rather than individual, and gives...
Read more
Mar 01, 2021
Roots of Obesity: The Many Factors that Affect Our...
Dr. Olivia Barata Cavalcanti describes the nuances among countries across the globe on why obesity rates are rising, along with...
Read more
Feb 22, 2021
How and When We Can Head Back to the Office
Dr. Leana Wen speaks about the factors influencing an employer’s return to work strategy, as well as why a constant revaluation of...
Read more
Feb 08, 2021
The Promise of the COVID-19 Vaccines and the...
Dr. Wachter tells us why distribution has been a “hot mess”; why we should run - not walk - to get vaccinated once our name is...
Read more
Jan 23, 2021
How to be Time Smart: Lessons from a Harvard...
Dr. Whillans speaks about our most valuable and finite resource: time. She shares common traps that leave us feeling ‘time poor’,...
Read more
Jan 11, 2021
The American Medical Association’s Commitment to...
Dr. Susan Bailey explores how the AMA has worked to confront racism, an insiduous threat to public health.
Read more
Showing items 111-120 of 132